Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-2mbcq Total loading time: 0 Render date: 2025-04-29T20:41:50.506Z Has data issue: false hasContentIssue false

23 - Colorectal Metastases: Chemoembolization

from PART III - ORGAN-SPECIFIC CANCERS

Published online by Cambridge University Press:  18 May 2010

By
Catherine M. Tuite
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Catherine M. Tuite
Affiliation:
Assistant Professor, Radiology University of Pennsylvania Medical Center Philadelphia, PA
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

The prognosis of patients with colorectal carcinoma is related to the degree of penetration of the primary tumor through the bowel wall, the presence or absence of nodal involvement and the presence or absence of distant metastases (1–3). In 2005, there were an estimated 104,950 new cases of colon cancer in the United States and 56,290 deaths from the disease (4). Autopsy series have shown up to 38% of patients who die from colorectal cancer may have the liver as the sole site of metastases (6). Even for patients with other sites of involvement, more than 50% die from metastatic liver disease (7). Several studies establish that resection of colorectal liver metastases improves long-term survival (7–9); however, for the 75% of patients with colorectal liver metastases found to be unresectable, palliative treatments remain an option. Since the late 1990s, systemic chemotherapy regimens have changed significantly, and there are now five active agents used to treat advanced disease, including those that target angiogenesis and epidermal growth factor receptor (10). Despite the improved response rates and progression-free survival obtained by these agents, especially when given in combination (11–14), most patients eventually develop disease progression. Chemoembolization may be offered to these patients, particularly those with liver-dominant metastases.

Chemoembolization is one of several regional therapies for colorectal liver metastases. It is the only one that provides a two-fold line of attack, since it involves the simultaneous infusion of chemotherapeutic and embolic agents.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 273 - 279
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Steinberg, S M, Barkin, J S, Kaplan, R S, et al. Prognostic indicators of colon tumors: The Gastrointestinal Tumor Study Group experience. Cancer, 1986 May 1; 57( 9 ): 1866–1870.3.0.CO;2-T>CrossRefGoogle Scholar
Chafai, N, Chan, C L, El, Bokey, et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer?Colorectal Dis, 2005 Mar; 7( 2 ): 176–181.CrossRefGoogle Scholar
Stangl, R, Altendorf-Hofmann, A, Charnley, R M, et al. Factors influencing the natural history of colorectal liver metastases. Lancet, 1994; 343: 1405–1410.CrossRefGoogle ScholarPubMed
American Cancer Society: Cancer Facts and Figures 2005 Atlanta, GA: American Cancer Society, 2005.
Gilbert HA, Kagan AR. Metastases: Incidence, detection and evaluation without histologic confirmation. In: Weiss, L (ed.), Fundamental Aspects of Metastasis, pp. 385–405. Amsterdam: North Holland, 1976.Google Scholar
Liu, L, Shang, W, and Jiang, H. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol, 2003; 9( 2 ): 193–200.CrossRefGoogle Scholar
Wagner, J S, Adson, M A, Heerden, J A, et al. The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment. Ann Surg, 1984;199: 502–508.CrossRefGoogle ScholarPubMed
Wanebo, H J, Semoglou, C, Attiyeh, F, et al. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg, 1978; 135: 81–85.CrossRefGoogle ScholarPubMed
Bramhall, S R, Gur, U, Coldham, C, et al. Liver resection for colorectal metastases. Ann R Coll Surg Engl, 2003; 85: 334–339.CrossRefGoogle ScholarPubMed
Bartlett, D L, Berlin, J, Lauwers, G Y, et al. Chemotherapy and regional therapy of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol, 2006; 13( 10 ): 1284–1292.CrossRefGoogle Scholar
Douillard, J Y, Cunningham, D, Roth, A D, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 200; 355: 1041–1047.CrossRefGoogle Scholar
Goldberg, R M, Sargent, D J, Morton, R F, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 2004 Jan 1; 22( 1 ): 23–30.CrossRefGoogle Scholar
Rothenberg, M L, Am, Oza, Bigelow, R H, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after inrinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol, 2003; 21: 2059–2069.CrossRefGoogle ScholarPubMed
Rothenberg, M L, LaFleur, B, Levy, D E, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol, 2005; 23: 9265–9274.CrossRefGoogle ScholarPubMed
Nakamura, H, Hashimoto, T, Oi, H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology, 1989; 170: 783–786.CrossRefGoogle ScholarPubMed
Sasaki, Y, Imaoka, S, Kasugai, H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer, 1987; 60: 1194–1203.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Konno, T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer, 1990; 66: 1897–1903.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Egawa, H, Maki, A, Mori, K, et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol, 1990; 44( 2 ): 109–114.Google Scholar
Kruskal, J B, Hlatky, L, Hahnfeldt, P, et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol, 1993; 4( 6 ): 741–747.CrossRefGoogle Scholar
Ramsey, D E, Kernagis, L Y, Soulen, M C, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol, 2002; 13( 9 Pt 2): S211–221.CrossRefGoogle Scholar
Li, X, Feng, G S, Zheng, C S, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol, 2004; 10( 19 ): 2878–2882.CrossRefGoogle ScholarPubMed
Liao, X, Yi, J, Li, X, et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technol Med Sci, 2003; 23( 3 ): 280–282.Google Scholar
Camma, C, Shepis, F, Orlando, A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology, 2002; 224( 1 ): 47–54.CrossRefGoogle Scholar
Charnsangavej, C, Carrasco, C H, Wallace, S, et al. Hepatic arterial flow distribution with hepatic neoplasms: Significance in infusion chemotherapy. Radiology, 1987 Oct; 165( 1 ): 71–73.CrossRefGoogle Scholar
Pentecost, M J, Daniels, J R, Teitelbaum, G P, et al. Hepatic chemoembolization: Safety with portal vein thrombosis. J Vasc Interv Radiol, 1993 May–Jun; 4( 3 ): 347–351.CrossRefGoogle Scholar
Song, S Y, Chung, J W, Han, J K, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: Incidence, predisposing factors and clinical outcome. J Vasc Interv Radiol, 2001; 12: 313–320.CrossRefGoogle ScholarPubMed
Kim, W, Clark, TWI, Baum, R A, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol, 2001; 12: 965–968.CrossRefGoogle ScholarPubMed
Geschwind, J F, Kaushik, S, Ramsey, D E, et al. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol, 2002; 13: 1163–1166.CrossRefGoogle ScholarPubMed
Stuart, K. Chemoembolization in the management of liver tumors. The Oncologist, 2003; 8: 425–437.CrossRefGoogle ScholarPubMed
Kan, Z, Ivancev, K, Hagerstrand, I, et al. In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol, 1989; 30( 4 ): 419–425.CrossRefGoogle Scholar
Kan, Z, Sato, M, Ivancev, I, et al. Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: Experimental study in several animal species. Radiology, 1993; 186( 3 ): 861–866.CrossRefGoogle Scholar
Kobayashi, H, Hidaka, H, Kajiya, Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn, 1986; 27( 2 ): 139–147.CrossRefGoogle Scholar
Tellez, C, Benson, A B 3rd, Lyster, M T, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer, 1998; 82( 7 ): 1250–1259.3.0.CO;2-J>CrossRefGoogle Scholar
Solomon, B, Soulen, M C, Baum, R A, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-c, ethiodol and polyvinyl alcohol: Prospective evaluation of response and survival in U.S. population. J Vasc Inter Radiol, 1999; 10: 793–798.CrossRefGoogle ScholarPubMed
Liu, D M, Salem, R, Bui, J T, et al. Angiographic considerations in patients undergoing liver directed therapy. J Vasc Interv Radiol, 2005; 16: 911–935.CrossRefGoogle ScholarPubMed
Borner, M, Castiglione, M, Triller, J, et al. Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol, 1992; 3( 2 ): 113–115.CrossRefGoogle Scholar
Leung, D A, Goin, J E, Sickles, C, et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol, 2001; 12: 321–326.CrossRefGoogle ScholarPubMed
Berger, D H, Carrasco, C H, Hohn, D C, et al. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: Post-treatment management and complications. J Surg Oncol, 1995; 60: 116–121.CrossRefGoogle ScholarPubMed
Sakamoto, I, Aso, N, Nagaoki, K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics, 1998; 18: 605.CrossRefGoogle ScholarPubMed
Chung, J W, Park, J H, Han, J K, et al.Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology, 1996; 198( 1 ): 33–40.CrossRefGoogle Scholar
Soulen, M C. Chemoembolization of hepatic malignancies. Oncology, 1994; 8( 4 ): 77–89.Google Scholar
Martinelli, D J, Wadler, S, Bakal, C W, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer, 1994; 74( 6 ): 1706–1712.3.0.CO;2-J>CrossRefGoogle Scholar
Kobayashi, H, Inoue, H, Shimada, J, et al. Infra-arterial injection of doxorubicin/mitomycin-C lipiodol suspension in liver metastases. Acta Radiol, 1987; 28( 3 ): 275–280.CrossRefGoogle Scholar
Kameyama, M, Imaoka, S, Fukuda, I, et al. Delayed washout of intratumor blood flow is associated with good response to intra-arterial chemoembolization for liver metastasis of colorectal cancer. Surgery, 1992; 114( 1 ): 97–101.Google Scholar
Lang, E K and Brown, C L. Colorectal metastasis to the liver: Selective chemoembolization. Radiology, 1993; 189:417–422.CrossRefGoogle Scholar
Feun, L G, Reddy, K R, Yrizarry, J M, et al. A phase II study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol, 1994; 17( 5 ): 405–410.CrossRefGoogle Scholar
Stuart, K, Huberman, M, Posner, M, et al. Chemoembolization for colorectal liver metastases [abstract]. Proc Am Soc Clin Oncol, 1995; 14( 439 ): 190.Google Scholar
Lorenz, M, Hermann, G, Kirkowa-Reimann, M, et al. Temporary chemoembolization of colorectal liver metastases with degradable starch microspheres. Eur J Surg Oncol, 1989; 15: 453–462.Google ScholarPubMed
Aronsen, K F, Hellkant, C, Holmberg, J, et al. Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs. Eur Surg Res, 1979; 11: 99–106.CrossRefGoogle ScholarPubMed
Starkhammar, H, Hakansson, L, Morales, O, et al. Intraarterial mitomycin-C treatment of unresectable liver tumors: Preliminary results on the effect of degradable starch microspheres. Acta Oncol, 1987; 26: 295–300.CrossRefGoogle Scholar
Wollner, I S, Walker-Andrews, S C, Smith, J E, et al. Phase II study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Drug Deliv, 1986; 4: 279–284.CrossRefGoogle Scholar
Daniels, S, Pentecost, M, Teitelbaum, G, et al. Hepatic artery chemoembolization for carcinoma of colon using angiostat collagen and cisplatin, mitomycin and doxorubicin: Response, survival and serum drug levels. Proc Am Soc Clin Oncol, 1992; 11: 171.Google Scholar
Meakem, T J III, Unger, E C, Pond, G D, et al. CT findings after hepatic chemoembolization. J Comput Assist Tomogr, 1992; 16( 6 ): 916–920.CrossRefGoogle ScholarPubMed
Sanz-Altimira, P M, Spence, L D, Huberman, M S, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: A phase II trial. Dis Colon Rectum, 1997; 40( 7 ): 770–775.CrossRefGoogle Scholar
Bavisotto, L M, Patel, N H, Althaus, S J, et al. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to the liver: A phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res, 1999; 5( 1 ): 95–109.Google Scholar
Salman, H S, Cynamon, J, Jagust, M, et al. Randomized phase II trial of embolization versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer, 2002; 2( 3 ): 173–179.CrossRefGoogle Scholar
Muller, H, Nakchbandi, V, Chatzisavvidis, I, et al. Repetitive chemoembolization with melphalan plus intraarterial immunochemotherapy with 5-fluorouracil and granulocyte-macrophage colony stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology, 2003; 50( 54 ): 1919–1926.Google Scholar
Popov, I, Lavrnic, S, Jelic, S, et al. Chemoembolization for liver metastases from colorectal carcinoma: Risk or benefit. Neoplasma, 2002; 49( 1 ): 43–48.Google Scholar
Voigt, W, Behrmann, C, Schlueter, A, et al. A new chemoembolization protocol in refractory liver metastases of colorectal cancer: A feasibility study. Onkologie, 2002; 25( 2 ): 158–164.Google Scholar
Santini, D, Vincenzi, B, Schiavon, G, et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first-line chemotherapy in advanced colorectal cancer patients: Phase II study. Cancer Chemother Pharmacol, 2006 Aug 31 [Epub ahead of print].Google Scholar
Goldberg, R M, Sargent, D J, Morton, R F, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial. J Clin Oncol, 2006; 24( 21 ): 3347–3353.CrossRefGoogle Scholar
Vogl, T J, Mack, M G, Balzer, J O, et al. Liver metastases: Neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology, 2003; 229: 457–464.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×